Organizational Structures of Process Development and Manufacturing Support - How to strike a balance between site autonomy and global coordination. - BioPharm International

ADVERTISEMENT

Organizational Structures of Process Development and Manufacturing Support
How to strike a balance between site autonomy and global coordination.


BioPharm International
Volume 24, Issue 9, pp. 32-36


Konstantin Konstantinov
The successful evolution of biotech companies has resulted in their expansion into complex multisite international structures. This transformation requires the establishment and coordination of various distributed functions, including manufacturing, manufacturing support (MS), and process development (PD). While such decentralization may offer some advantages, such as fast responses to local crises, use of local talent, cost reductions, and certain regulatory benefits, decentralization also poses significant organizational challenges. To address these challenges, companies have to find the right balance between site autonomy and functional centralization, so that the potential of each site is fully enabled, while a high level of coordination between sites is maintained. This article analyzes several structural alternatives for global PD organization, versions of which can be found in the biotech industry today. Two global structures that can potentially provide a practical solution for most cases will be proposed. These models are idealized, not reflecting any particular organization. Although this discussion focuses on PD, some of the solutions are fully applicable to MS. In the long term, the global PD and MS functions are unlikely to remain static. The evolution of every company requires periodic review and optimization of PD and MS, so that they adequately reflect the needs, size, and the maturity of the organization as it becomes a well-engineered global enterprise.

The authors discussed the PD organization structure issues with the management of multiple large biotech and biopharmaceutical companies involved in therapeutic protein manufacturing (1). The focus was on the following:

  • Definition of responsibilities, in particular in the area of overlap between manufacturing and development
  • Global structures of PD and MS
  • Allocation of PD and MS functions in the global decentralized company
  • Additional cross-functional means for enhancing coordination.

While all companies have their own structures, there are general concepts and patterns that are reproducible. Using the gathered information in combination with the authors' own experience, organizational models were developed that cover a broad spectrum of options spanning from complete decentralization to full centralization. These models do not represent the structure of any particular company, but capture the essence of the existing opportunities.

The existing structures are not static but continue to evolve, thus reflecting the progress and the specifics of each organization. Despite many differences, often resulting from the personal preference of top management, there is a clear trend towards global alignment.

Most companies have separate MS and PD functions. Furthermore, the MS groups are always colocated with the manufacturing departments they are supporting. Because this model is common and offers some important advantages, the authors considered it as a standard in the analysis. The advantages of this approach include speed of response to urgent manufacturing needs and shielding of PD from short-term daily problems in the plant, so that resources are focused on long-term strategic projects and innovation (2). In some cases, a central MS group is responsible for the coordination and standardization between the distributed MS networks.


Table I: Responsibilities of process development (PD) and manufacturing support (MS).
Table I summarizes the responsibilities of the MS and PD groups. In this illustration, the MS groups serve as the first line of defense. Because speed is one of the main requirements, local presence, including on-the-floor support, is essential. MS focuses on the manufacturing processes at the particular site and is often a structural part of the manufacturing organization. It is responsible for the day-to-day issues, including deviation investigations, continuous improvement, process monitoring, data mining, and process transfer to the local site. Typically, MS is not involved in complex, exploratory, long-term projects. These projects are handled by PD, and developed in close coordination with MS and manufacturing.

On the other hand, PD is responsible for larger life-cycle management projects, development and transfer of new processes, new technology platforms, and manufacturing support of complex projects requiring intense experimental and analytical work. The PD group can be centralized or decentralized, residing at several sites that provide remote services to various internal customers.

While a definition of the responsibilities of MS and PD is helpful, it is difficult to define a clear line between the two. Accepting a certain level of healthy overlap and ambiguity is practical, because this can serve as a bridge between the two functions, thus preventing dangerous gaps. The complexity of biotech manufacturing results in a continuum of projects, some of which cannot be clearly allocated to only MS or PD.

The coordination between MS and PD is a critical element of the biotech enterprise. Structurally, these groups exist as independent departments under different management. As such, it is essential that their activities, procedures, objectives, priorities, and methodology be aligned. This alignment can be achieved by properly designed business processes involving both organizations, including but not limited to joint teams, committees, periodic reviews, and symmetrical functional structures. Proper alignment allows for an optimal response to rapidly changing priorities, fluidity, coordinated resource allocation, and global utilization of knowledge generated at different locations.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here